Cuprate(4-), [μ-[[7,7'-[[6-[(2-hydroxyethyl)amino]-1,3,5-triazine-2,4-diyl]diimino]bis[4-(hydroxy-κO)-3-[[2-(hydroxy-κO)-5-sulfophenyl]azo-κN1]-2-naphthalenesulfonato]](8-)]]di-, tetrasodium

Endpoint summary

Description of key information

The NOAEL of Everdirect SH12 >1000 mg/kg B.W. (OECD TG407).

Key value for chemical safety assessment

Repeated dose toxicity: via oral route - systemic effects

Link to relevant study records

Reference

Endpoint:

repeated dose toxicity: oral, other

Type of information:

experimental study

Adequacy of study:

key study

Study period:

From May 30, 2016 to January 04, 2017

Reliability:

1 (reliable without restriction)

Rationale for reliability incl. deficiencies:

guideline study

Qualifier:

according to guideline

Guideline:

OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)

GLP compliance:

yes

Species:

rat

Strain:

Sprague-Dawley

Sex:

male/female

Details on test animals or test system and environmental conditions:

- Source: BioLASCO Taiwan Co., Ltd.
- Age at study initiation: about 4-week old
- Housing: Male and female rats were fed, respectively. Two rats per cage in an autoclaved polyethylene cage.
- Acclimation period: 1 week
- Temperature (°C): 22 ± 3 °C
- Humidity (%): 55 ± 15%
- Photoperiod: 12-hrs dark / 12-hrs light

Route of administration:

oral: gavage

Vehicle:

water

Dose / conc.:

62.5 mg/kg bw/day (nominal)

Remarks:

Low dose group

Dose / conc.:

250 mg/kg bw/day (nominal)

Remarks:

Medium dose group

Dose / conc.:

1 000 mg/kg bw/day (nominal)

Remarks:

High dose group

No. of animals per sex per dose:

For male: six
For female: six

Control animals:

yes, concurrent vehicle

Clinical signs:

no effects observed

Mortality:

no mortality observed

Body weight and weight changes:

no effects observed

Food efficiency:

no effects observed

Ophthalmological findings:

no effects observed

Haematological findings:

effects observed, non-treatment-related

Description (incidence and severity):

For male rats:
The mean corpuscular hemoglobin concentration (MCHC) of low dose group and lymphocyte in all treatment groups were lower than control group (ρ<0.05). The eosinophil of low and high dose groups and monocyte of medium dose group were higher than control group (ρ<0.05).
For female rats:
The hematocrit (Hct) and mean corpuscular volume (MCV) of medium and high dose groups were significantly lower than control group (ρ<0.05). The mean corpuscular hemoglobin concentration (MCHC) of medium and high dose groups were significantly higher than control group (ρ<0.05).

Clinical biochemistry findings:

effects observed, non-treatment-related

Description (incidence and severity):

For male rats:
The triglyceride (TG) of high dose group was significantly higher than control group (ρ<0.05).
For female rats:
The alkaline phosphatase (ALP) and the total bile acid (TBA) of low dose group were significantly lower than control group (ρ<0.05). The Ca and globulin of low dose group were significantly higher than control group (ρ<0.05). The alanine aminotransferase (ALT), the triglyceride (TG) and the total bile acid (TBA) of medium dose group were significantly lower than control group (ρ<0.05). The creatinine and the triglyceride (TG) of high dose group were significantly lower than control group (ρ<0.05).

Urinalysis findings:

no effects observed

Organ weight findings including organ / body weight ratios:

effects observed, non-treatment-related

Description (incidence and severity):

For male rats:
The absolute weight of kidney in high dose groups was significantly higher than control group (ρ<0.05). The relative organ weight of kidney in high dose group was significantly higher than control group (ρ<0.05).
For female rats:
The absolute weight of adrenal gland in high dose groups was significantly lower than control group (ρ<0.05). The relative organ weight of adrenal gland in high dose group was significantly lower than control group (ρ<0.05).

Histopathological findings: non-neoplastic:

effects observed, non-treatment-related

Description (incidence and severity):

Kidney
Only one male rat in the high dose group showed a focal, slight tubular cyst in the kidney. Two Female rats in the control and one male rat in the high dose groups showed focal, slight tubular infarct in the kidney. Only one female rat in the control group showed focal, slight tubular regeneration in the kidney.
Liver
Only one female rat in the control group presented focal, slight necrosis in the liver.
Lung
One male rat in the control and one female rat in the high dose groups presented focal to multifocal, minimal to slight inflammation in the lungs.
Thyroid gland
Only one female rat in the high dose group presented focal, slight, mononuclear cell infiltration in the thyroid gland. Only one female rat in the high dose group presented focal, slight, macrophage infiltration in the thyroid gland.

Dose descriptor:

NOAEL

Effect level:

> 1 000 mg/kg bw/day (nominal)

Based on:

test mat.

Sex:

male/female

Basis for effect level:

body weight and weight gain

clinical biochemistry

clinical signs

food efficiency

haematology

histopathology: non-neoplastic

mortality

ophthalmological examination

organ weights and organ / body weight ratios

urinalysis

Critical effects observed:

no

Conclusions:

According to OECD 407 test method, the NOAEL of Everdirect SH12 for the rats was great than 1000 mg/kg B.W..

Executive summary:

This test using the procedures outlined in the SuperLab Study Plan for M62-151100083001EN and OECD 407 (OECD, 2008).The test article was administered to the three treatment groups by oral gavage in a dose of 62.5, 250 and 1000 mg/kg B.W. for 28 consecutive days. There were six male and six female Sprague-Dawley rats in each group. Clinical observation of the rats was carried out daily and the body weight and feed intake of the rats were recorded once a week. Results of the study indicated that rats in all group gained weight normally and did not show any abnormal clinical signs and ophthalmological examination during the study period. At end of the study, there were no significant abnormalities of the urinalysis,haematologyand clinical biochemistry parameters between the treatment and control groups. Necropsy and histopathological examination indicated that no treatment-related change was found. On the basis of the test results given above, the NOAEL of Everdirect SH12 for the rats was great than 1000 mg/kg B.W..

Endpoint conclusion

Endpoint conclusion:

no adverse effect observed

Dose descriptor:

NOAEL

1 000 mg/kg bw/day

Study duration:

subacute

Species:

rat

Repeated dose toxicity: inhalation - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: inhalation - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - systemic effects

Endpoint conclusion

Endpoint conclusion:

no study available

Repeated dose toxicity: dermal - local effects

Endpoint conclusion

Endpoint conclusion:

no study available

Additional information

Repeated dose toxicity: via oral route-systemic effects

The test article was administered to the three treatment groups by oral gavage in a dose of 62.5, 250 and 1000 mg/kg B.W. for 28 consecutive days. There were six male and six female Sprague-Dawley rat in each group. Clinical observation of the rats was carried out daily and the body weight and feed intake of the rats were recorded once a week. Results of the study indicated that rats in all group gained weight normally and did not show any abnormal clinical signs and ophthalmological examination during the study period. At end of the study, there were no significant abnormalities of the urinalysis, haematology and clinical biochemistry parameters between the treatment and control groups. Necropsy and histopathological examination indicated that no treatment-related change was found.On the basis of the test results given above, the NOAEL of Everdirect SH12 for the rats was great than 1000 mg/kg B.W..